To understand the impact of this favorable metabolic profile on antitumor activity and persistence in vivo, 40A3Bz dnTGFβRII SMART CAR-Ts were administered at doses of 0.3 × 106, 1 × 106, 3 × 106, and 6 × 106 in an efficacy study in the 22RV1–TGF-β model, similar to the study described in Figure 5G, but to postpone the onset of graft-versus-host disease, NSG MHC class I/II–deficient mice were used. This evidence concerns the gene TGFB1 and graft versus host disease.